Announcement PDF Tuesday, 30th September 2025 Dear Shareholder Atomo Diagnostics Limited – Annual General Meeting of Shareholders, Friday 31 October 2025 at 10:00am (AEDT). Notice is hereby given that the Annual General Meeting of Shareholders of Atomo Diagnostics Limited (“Company”) will be held in-person at Level 1, 3-5 George Street, Leichhardt NSW 2040 at 10:00am (AEDT) on Friday 31 October 2025 (“Annual General Meeting”, “AGM” or “Meeting”). In accordance with recent amendments to the Corporations Act 2001, the Company is sending this notification letter instead of dispatching physical copies of the Notice of AGM. The Notice of AGM and accompanying explanatory statement (“Meeting Materials”) are being made available to shareholders electronically. This means that: - You can access the Meeting Materials online at the Company’s website https://investors.atomodiagnostics.com/investor-centre/ or at the Company’s share registry’s website https://www.investorserve.com.au/ through Investor Serve by logging in and selecting Company Announcements from the main menu. - A complete copy of the Meeting Materials has been posted to the Company’s ASX Market announcements page at www.asx.com.au under the Company’s ASX code “AT1”. - If you have provided an email address and have elected to receive electronic communications from the Company, you will receive an email to your nominated email address with a link to an electronic copy of the Meeting Materials and instructions to vote online. If you would like to receive electronic communications from the Company in the future, please update your communication elections online at https://www.investorserve.com.au/. If you have not yet registered, you will need your shareholder information including SRN/HIN details. If you are unable to access the Meeting Materials online please contact our share registry Boardroom Pty Limited on enquiries@boardroomlimited.com.au or by phone on + 61 2 9290 9600 (outside Australia) or 1300 737 060 (within Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday, to obtain a copy. The Company strongly recommends to Shareholders to lodge a directed proxy as soon as possible in advance of the meeting even if they are planning to attend the meeting on the day. Yours sincerely, Mathew Watkins Company Secretary Atomo Diagnostics Limited w . a t o m o d ia g n o st ic s.c o m | a . Le ve l 1, 3-5 Ge o rg e St re e t , Le ic h h a rd t , N SW , 20 4 0 Au st ra lia | p . +6 1 2 9 0 9 9 4 750 | P a g e 1 ATOMO DIAGNOSTICS LIMITED ACN 142 925 684 Notice of Annual General Meeting Explanatory Statement and Proxy Form Date of Meeting: Friday, 31 October 2025 Time of Meeting: 10:00am (AEDT) Place of Meeting: Level 1, 3 - 5 George Street Leichhardt NSW 2040 This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety. If shareholders are in doubt as to how they should vote, they should seek advice from their accountant, solicitor or other professional advisor without delay. ATOMO DIAGNOSTICS LIMITED ACN 142 925 684 Registered office: Level 1, 3-5 George St. Leichhardt NSW 2040 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Annual General Meeting (“AGM” or “Meeting”) of Members of Atomo Diagnostics Limited (the “Company”) will be held at Level 1, 3 - 5 George Street, Leichhardt, NSW 2040 at 10:00am (AEDT) on Friday, 31 October 2025. Note that physical attendance will be limited and available only on an RSVP basis. To register your interest in attending in person, please email kathryn.curley@atomodiagnostics.com for confirmation. Members are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off date for proxy voting as set out in this Notice. To lodge your proxy, please follow the directions on your personalised proxy form which will be delivered to you by email or post (depending on your communication preferences). The Meeting can be attended using the following details: When: Friday, 31 October 2025 at 10:00am (AEDT) Where: Level 1, 3 - 5 George Street Leichhardt NSW 2040 Topic: Atomo Diagnostics Limited – 2025 Annual General Meeting If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the Meeting, the Company will make further information available through the ASX website at asx.com.au (ASX: AT1) and on its website at https://investors.atomodiagnostics.com/investor-centre/. Shareholders should therefore monitor the Company’s website and its ASX announcements for any updates about the Meeting. The Company is happy to accept and answer questions submitted prior to the Meeting by email to Mathew Watkins at Mathew.Watkins@vistra.com. The Company will address relevant questions during the Meeting or by written response after the Meeting (subject to the discretion of the Company not to respond to unreasonable and/or offensive questions). AGENDA The Explanatory Statement and proxy form, which accompany and form part of this Notice, include defined terms and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement and the proxy form in their entirety. ORDINARY BUSINESS Receipt and Consideration of Financial Statements & Reports To receive and consider the 2025 Annual Report of the Company and its controlled entities for the financial year ended 30 June 2025, which includes the Financial Report, the Directors' Report and the Auditor's Report. Note: Except for as set out in Resolution 1, there is no requirement for shareholders to approve these reports. Accordingly, no resolution will be put to shareholders on this item of business. Resolution 1: Adoption of Remuneration Report To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report (included in the Directors' report) for the financial year ended 30 June 2025 be adopted.” Resolution 2: Election of Mr Patrick Cook as a Director of the Company To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purpose of Rule 20.3(b) of the Constitution and for all other purposes, Mr Patrick Cook who automatically retires as a Director in accordance with the Constitution of the Company, and who, being eligible, offers himself for election, be elected as a Director of the Company.” Resolution 3: Election of Mr Anthony May as a Director of the Company To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purpose of Rule 20.3(b) of the Constitution and for all other purposes, Mr Anthony May who automatically retires as a Director in accordance with the Constitution of the Company, and who, being eligible, offers himself for election, be elected as a Director of the Company.” Resolution 4: Ratification of prior issue of Shares to Pitt Street Research Pty Ltd (and/or their nominee(s)) To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve, ratify and confirm the issue and allotment of 2,000,000 fully paid ordinary shares (“Shares”) in the Company to Pitt Street Research Pty Ltd (and/or their nominee(s)), at a deemed issue price of $0.021 (2.1 cents) per Share, as part consideration for analyst research service on the terms and conditions set out in the Explanatory Statement.” Resolution 5: Approval to Grant Options to Mr Patrick Cook (and/or his nominee(s)) To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,400,000 Options in the Company to Mr Patrick Cook, (and/or his nominee(s)), Non-Executive Chair of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.” Resolution 6: Approval to Grant Options to Mr Anthony May (and/or his nominee(s)) To consider and, if thought fit, to pass the following resolution as an ordinary resolution: 2 “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 700,000 Options in the Company to Mr Anthony May (and/or his nominee(s)), Non-Executive Director of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.” Resolution 7: Approval to Grant Options to Dr Cheri Walker (and/or her nominee(s)) To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,000,000 Options in the Company to Dr Cheri Walker (and/or her nominee(s)), Non-Executive Director of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.” SPECIAL BUSINESS Resolution 8: Approval of 10% Placement Facility To consider and, if thought fit, pass the following resolution as a special resolution: “That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, shareholders approve the issue of Equity Securities up to the equivalent of 10% of the Company’s fully paid ordinary issued capital (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Statement.” Resolution 9: Amendments of Constitution To consider and, if thought fit, pass the following resolution as a special resolution: “That for the purposes of section 136(2) of the Corporations Act, the Constitution of Atomo Diagnostics Limited be modified by making the amendments contained within the Explanatory Statement, with effect from the conclusion of the Meeting.” By the order of the Board Mathew Watkins Company Secretary 23 September 2025 3 Notes 1. Entire Notice: The details of the resolutions contained in the Explanatory Statement accompanying this Notice of Meeting should be read together with, and form part of, this Notice of Meeting. 2. Record Date: The Company has determined that for the purposes of the Annual General Meeting, shares will be taken to be held by the persons who are registered as holding the shares at 7.00pm, 48 hours before the date of the AGM. Only those persons will be entitled to vote at the AGM and transfers registered after that time will be disregarded in determining entitlements to attend and vote at the AGM. 3. Proxies a. b. c. d. e. f. g. h. 4. Votes at the AGM may be given personally or by proxy, attorney or representative. Each member has a right to appoint one or two proxies. A proxy need not be a member of the Company. If a member is a company it must execute under its common seal or otherwise in accordance with its constitution or the Corporations Act. Where a shareholder is entitled to cast two or more votes, the shareholder may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If a shareholder appoints two proxies, and the appointment does not specify the proportion or number of the shareholder’s votes, each proxy may exercise half of the votes. If a shareholder appoints two proxies, neither proxy may vote on a show of hands. A proxy must be signed by the shareholder or his or her attorney who has not received any notice of revocation of the authority. Proxies given by corporations must be signed in accordance with corporation’s constitution and Corporations Act. To be effective, proxy forms must be received by the Company’s share registry no later than 48 hours before the commencement of the AGM, this is no later than 10:00am (AEDT) on Wednesday, 29 October 2025. Any proxy received after that time will not be valid for the scheduled Meeting. Corporate Representative Any corporate shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s representative. The authority may be sent to the Company and/or share registry in advance of the Meeting or handed in at the Meeting when registering as a corporate representative. 5. Voting Exclusion Statement: Resolution 1 In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity), and the Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of, a member of the Key Management Personnel (“KMP”), details of whose remuneration are included in the remuneration report, or a Closely Related Party of such a member (either being a “KMP voter”), unless the KMP voter is casting a vote on behalf of a person who is not a KMP voting (including as a proxy) and either: a. b. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or the KMP voter is by the Chair of the Meeting and the appointment of the Chair as proxy: i. does not specify the way the proxy is to vote on the Resolution; and ii. expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the key KMP for the Company or the consolidated entity. If you appoint the Chair as your proxy and you do not direct the Chair on how to vote, you will be expressly authorising the Chair to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP for the Company. If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any proxies which do not indicate on their proxy form the way the Chair must vote, in favour of the Resolution. In exceptional circumstances, the Chair may change their voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting. If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act. A further restriction also applies to KMP and their Closely Related Party voting undirected proxies on this Resolution – see Restriction on KMPs voting undirected proxies below. Resolution 2 There are no voting exclusions on this Resolution. Resolution 3 There are no voting exclusions on this Resolution. Resolution 4 The Company will disregard any votes cast in favour of this Resolution by or on behalf of any person, and any associates of that person, who participated in the issue of securities. 4 However, this does not apply to a vote cast in favour of the Resolution by: a. a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or b. the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and ii. the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Resolutions 5 – 7 The Company will disregard any votes cast in favour of each of Resolutions 5 through to 7 (respectively and separately) by or on behalf of  Mr Patrick Cook, Mr Anthony May, Dr Cheri Walker or any person(s) who will obtain a material benefit as a result of the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity), or  an associate of person referred to in the preceding paragraph. However, this does not apply to a vote cast in favour of the resolution by: (a) (b) (c) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Furthermore, a vote must not be cast as proxy on any Resolutions 5, 6 and 7 by a member of the Key Management Personnel (as defined by the Corporations Act) or a closely related party of Key Management Personnel. Resolution 8 As at the date of despatch of this Notice, the Company does not have approval to make an issue of Equity Securities under Listing Rule 7.1A.2 and, therefore, a voting exclusion statement on this Resolution is not required by Listing Rule 7.3A.7 as at that date. This is a Special Resolution requiring at least 75% of the votes cast by Shareholders entitled to vote to be in favour of the Resolution in order for it to pass. Resolution 9 There are no voting exclusions on this Resolution. This is a Special Resolution requiring at least 75% of the votes cast by Shareholders entitled to vote to be in favour of the Resolution in order for it to pass. 6. Restriction on KMPs voting undirected proxies: A vote must not be cast as proxy on Resolution 1 or Resolutions 5 through to 7 by a member of the KMP (as defined by the Corporations Act) or a Closely Related Party of a KMP. However, a person described above (a “Restricted Voter”) may cast a vote on behalf of a person who is not a Restricted Voter on Resolution 1 as a proxy if: a. b. The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or The Chair is the Restricted Voter and the written appointment of the Chair as proxy does not specify the way the proxy is to vote on the Resolution or expressly authorises the Chair to exercise the proxy even though the Resolution is connected directly or indirectly with the remuneration of a member of the KMP. If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP for the Company. 7. Enquiries Shareholders are invited to contact the Company Secretary on (03) 9692 7222 if they have any queries in respect of the matters set out in these documents. 5 EXPLANATORY STATEMENT Purpose of Information This Explanatory Statement (“Statement”) accompanies and forms part of the Company’s Notice of Annual General Meeting (“Notice”) for the 2025 Annual General Meeting (“Meeting”) will be held at Level 1, 3 - 5 George Street, Leichhardt NSW 2040 at 10.00am (AEDT) on Friday, 31 October 2025. The Notice incorporates, and should be read together, with this Statement. Receipt and consideration of Accounts & Reports A copy of the Annual Report for the financial year ended 30 June 2025 (which incorporates the Company's financial report, reports of the Directors (including the Remuneration Report) and the auditors) the Company's website https://investors.atomodiagnostics.com/announcements or via the Company's announcement platform on ASX. Alternatively, you may obtain a copy free of charge in hard copy form by contacting the Company by phone at 02 9099 4750 and you may request that this occurs on a standing basis for future years. There is no requirement for Shareholders to approve the Annual Report. Shareholders will have the opportunity at the Meeting to ask questions about or make comments on the 2025 Financial Report, the Directors’ Report, and the Auditor’s Report. Questions for the Company’s auditors relating to the conduct of the audit, preparation and contents of the audit report, accounting policies adopted by the Company in relation to the preparation of its financial statements, and the independence of the auditors in relation to the conduct of the audit, must be submitted no later than 5 business days before the Meeting to the Company Secretary at the Company's registered office. The auditor will be invited to attend and answer questions about the audit of the Company’s 2025 Annual Financial Statements. ORDINARY BUSINESS Resolution 1: Adoption of Remuneration Report Background Section 250R (2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put to the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the Directors or the Company. The Remuneration Report is set out in the Directors’ Report in the Company’s 2025 Annual Report. The Remuneration Report sets out the Company’s remuneration arrangements for the Directors and senior management of the Company. In accordance with section 250SA of the Corporations Act, shareholders will be provided with a reasonable opportunity to ask questions concerning, or make comments on, the Remuneration Report at the AGM. In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes that are cast are voted against the adoption of the Remuneration Report at two consecutive Annual General Meetings, shareholders will be required to vote at the second of those Annual General Meetings on a resolution (a “spill resolution”) that another meeting be held within 90 days at which all of the Company’s Directors (other than the Managing Director) must go up for re-election. At its last annual general meeting, a Spill Resolution was put to shareholders, as a result of there having been two consecutive Annual General Meetings (including the last annual general meeting) at which at least 25% of the votes cast on the Remuneration Report resolution were cast against the Remuneration Report Resolution. The Spill Resolution put to shareholders at the last annual general meeting was not passed by shareholders therefore a Spill Resolution is not relevant for this Annual General Meeting. The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration Report at the Meeting when reviewing the Company’s remuneration policies. 6 Board Recommendation Noting that each Director has a personal interest in their own remuneration from the Company (as such interests are described in the Remuneration Report) and, as described in the voting exclusions on this Resolution (set out in the Notice of AGM), that each Director (or any Closely Related Party of a Director) is excluded from voting their shares on this Resolution, the Directors encourages all eligible shareholders to cast their votes in favour of this Resolution. Voting Intention The Chair intends to vote all undirected proxies in favour of this resolution. Voting Exclusions A voting exclusion statement for this resolution is set out in Note 5 above. Resolution 2: Election of Mr Patrick Cook as a Director of the Company Background On 2 May 2025, Mr Patrick Cook was appointed as a Director of the Company pursuant to Rule 20.3(a) of the Constitution. In accordance with Rules 20.3(b) and 20.6(b) of the Constitution, any appointed Director automatically retires at the next AGM and is eligible for election by that AGM. Consequently, Mr Cook will retire at this year’s AGM and offers himself for election. Mr Cook is an experienced Non-Executive Director and Chair with over 20 years of board level experience and over 30 years’ experience in senior executive positions in medical devices & point-of-care diagnostics sectors within multinational and listed biotechnology companies Mr Cook currently serves as Committee Member of the Executive at Animal Ethics Committee QUT and has previously served as Non-Executive Director & Chair, at Workplace Drug Testing Australasia Ltd and eWaste Connection Ltd.. Mr Cook also served as a Board Member at Prostate Cancer Foundation of Australia (Qld), Mr Cook is a Fellow of the Australian Institute of Company Directors and holds degrees in Science and Marketing. The Company considers Mr Cook as an independent director for all purposes. Board Recommendation The Board (with Mr Cook abstaining in his capacity as a Director) recommends that shareholders vote in favour of this Resolution as it considers that Mr Cook’s qualifications, experience, skills, and expertise are appropriate for the Board position and will enable him to act in the best interests of the Company and its shareholders. Voting Intention The Chair intends to vote all undirected proxies in favour of this Resolution. Voting Exclusions There are no voting exclusions on this Resolution. Resolution 3: Election of Mr Anthony May as a Director of the Company Background On 2 May 2025, Mr Anthony May was appointed as a Director of the Company pursuant to Rule 20.3(a) of the Constitution. In accordance with Rules 20.3(b) and 20.6(b) of the Constitution, any appointed Director automatically retires at the next AGM and is eligible for election by that AGM. Consequently, Mr May will retire at this year’s AGM and offers himself for election. Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With extensive experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a 7 strong track record in business leadership and strategic growth. Mr May is a member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine and holds a bachelor’s degree in science. The Company considers Mr May as an independent director for all purposes. Board Recommendation The Board (with Mr May abstaining in his capacity as a Director) recommends that shareholders vote in favour of this Resolution as it considers that Mr May’s qualifications, experience, skills, and expertise are appropriate for the Board position and will enable him to act in the best interests of the Company and its shareholders. Voting Intention The Chair intends to vote all undirected proxies in favour of this Resolution. Voting Exclusions There are no voting exclusions on this Resolution. Resolution 4: Ratification of prior issue of Shares to Pitt Street Research Pty Ltd (and/or their nominee(s)) Background On 15 November 2024, the Company engaged the services of Pitt Street Research Pty Ltd (“Pitt Street”) to provide independent analyst research coverage to the Company for a period of twelve months. The consideration for the service was agreed to be paid partly in cash and partly in Shares i.e. $30,000 plus GST in cash and issue 2,000,000 Shares in the Company at a deemed issue price of $0.021 (2.1 cents) each to Pitt Street. The cash was paid within 5 business days of entering into the agreement while the Shares were issued on 9 July 2025, following the completion of a successful Placement and Share Purchase Plan, as agreed. The Shares were issued without shareholder approval from the Company’s 15% placement capacity pursuant to ASX Listing Rule 7.1. Resolution 4 seeks Shareholder ratification for the issue of 2,000,000 Shares in the Company to Pitt Street Research Pty Ltd (and/or their nominee(s)). Listing Rules Listing Rule 7.1 allows the Company to issue new securities up to 15% of the existing capital of the Company in any 12-month period without the prior approval of shareholders, unless one of the exceptions in Listing Rule 7.2 applies. The shares issued were within the Company’s available placement capacity under ASX Listing Rules 7.1. Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of shareholders for the purposes of ASX Listing Rule 7.1 if the issue did not breach Listing Rule 7.1 at the time and shareholders subsequently approve it. The issue of the Shares to Pitt Street (and/or their nominee(s)) were within the Company's Listing Rule 7.1, did not fall within any of the exceptions in Listing Rule 7.2, and were not previously approved by Shareholders. The Company now seeks Shareholder approval of the issue pursuant to Listing Rule 7.4. If this Resolution is approved, the prior issue of 2,000,000 Shares will be excluded in calculating the Company’s 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without shareholder approval over the 12 month period following the issue date. If this Resolution is not approved, the prior issue of 2,000,000 Shares will be included in calculating the Company’s 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without shareholder approval over the 12 month period following the issue date,. Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining shareholder approval